Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options
- PMID: 16098845
- DOI: 10.1016/j.amjcard.2005.06.006
Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options
Abstract
In the summer of 2004, an evidence-based update of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines for management of hypercholesterolemia was published. This detailed assessment of 5 major clinical trials, published since the ATP III report in 2001, was designed to provide guidance for physicians in decision making for patients at high risk and very high risk. We have tried to summarize this assessment by suggesting the following to clinicians: (1) Calculate global risk of coronary artery disease (CAD) to determine an overall strategy for cholesterol management. (2) Emphasize the benefits of diet, exercise, and weight control or therapeutic lifestyle change, especially in those with lifestyle risk factors. (3) Use 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors (statins) as first-line drugs to reduce risk of CAD and stroke in those at moderate to high risk. (4) If statins are prescribed, use moderate doses that reduce plasma levels of low-density lipoprotein (LDL) cholesterol by > or = 30% to 40%. (5) Strongly consider statin therapy in those with diabetes (with the exception of severe hypertriglyceridemia). (6) Consider LDL cholesterol-lowering drug therapy for lipids in older patients at risk. (7) Consider adding either a fibrate or nicotinic acid in high-risk patients with elevated plasma triglyceride values or low levels of plasma high-density lipoprotein cholesterol after statin therapy has achieved the LDL cholesterol goal. (8) Continue to treat those at low risk in similar fashion as before. This update is to inform current physician judgment in this area. Further clinical trial data that may modify or extend these recommendations are eagerly awaited.
Similar articles
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001. J Am Coll Cardiol. 2004. PMID: 15358046 Review.
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E. Arterioscler Thromb Vasc Biol. 2004. PMID: 15297292 Review.
-
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.Curr Med Res Opin. 2001;17(1):60-73. Curr Med Res Opin. 2001. PMID: 11464448 Review.
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Curr Opin Cardiol. 2006 Jul;21(4):400-4. doi: 10.1097/01.hco.0000231412.15049.fb. Curr Opin Cardiol. 2006. PMID: 16755211 Review.
-
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.Am J Cardiol. 2005 Aug 22;96(4A):60E-66E. doi: 10.1016/j.amjcard.2005.06.007. Am J Cardiol. 2005. PMID: 16098846 Review.
Cited by
-
LDL Cholesterol Goal Attainment in Hypercholesterolemia: CEPHEUS Indonesian Survey.Acta Cardiol Sin. 2013 Jan;29(1):71-81. Acta Cardiol Sin. 2013. PMID: 27122687 Free PMC article.
-
High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia.Gut Liver. 2023 May 15;17(3):456-465. doi: 10.5009/gnl220133. Epub 2022 Nov 1. Gut Liver. 2023. PMID: 36317511 Free PMC article.
-
Long-term Management of the Adult Liver Transplantation Recipients.J Clin Exp Hepatol. 2021 Mar-Apr;11(2):239-253. doi: 10.1016/j.jceh.2020.06.010. Epub 2020 Jul 2. J Clin Exp Hepatol. 2021. PMID: 33746450 Free PMC article. Review.
-
Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: A cross-sectional Study.Health Promot Perspect. 2024 Jul 29;14(2):161-167. doi: 10.34172/hpp.42568. eCollection 2024. Health Promot Perspect. 2024. PMID: 39291051 Free PMC article.
-
Metabolic Syndrome and Nephrolithiasis Risk: Should the Medical Management of Nephrolithiasis Include the Treatment of Metabolic Syndrome?Rev Urol. 2015;17(3):117-28. Rev Urol. 2015. PMID: 26543426 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous